中文版

Coronary Artery Center


Overview

The Coronary Artery Center of Jiangsu Province Hospital was founded in 2011. It was originally developed from the Department of Cardiology, the only National Key Discipline of Jiangsu Province Hospital.

The center currently has 132 beds and employs 20 professionals, among whom 14 have senior professional titles, 9 are full professors, 5 are associate professors, 3 are doctoral supervisors and 9 are master tutors. 

In the field of coronary intervention and grafting, the center act as a leading position in Jiangsu Province and is located in an advanced status in China. Additionally, the gene therapy for ischemic myocardiopathy of the center has a high level of academic influence over the world.


Department Director 

Dr. Zhijian Yang

Professor in Cardiology

Chief of Coronary Artery Center

Subdecanal of Jiangsu Province Hospital

Dr. Zhijian Yang, director of coronary artery center, is an expert in the diagnosis and treatment of coronary heart disease. He graduated from the department of cardiovascular medicine, Peking University Health Science Center in 1994. He has been in the hospital for more than 22 years. At present, he is the vice director of the First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), vice chairman of the 93 Institute of Jiangsu Provincial Committee, Jiangsu provincial CPPCC member.

Academically, he served as the chairman of cardiovascular rehabilitation specialized committee of Rehabilitation Medical Association of Jiangsu, vice chairman of regenerative medicine specialized committee of Chinese Pharmaceutical Biotechnology Association and vice chairman of Jiangsu Province branch of cardiovascular Specialized Committee of Chinese Medical Association. At the same time, he is also a member of atherosclerosis committee of Chinese Association of Pathophysiology (International Atherosclerosis Association China branch), a member of the academic committee of cardiovascular interventional treatment and training center of the Chinese Medical Association and a member of seventh committee of Chinese Society of Cardiology.

In recent years, his team has established a total of 17 research projects and obtained the scientific research funds totaling more than 10 millions yuan. The research results have been published in PNAS, Curr Gene Ther, Am J Clin Nutr, J Thromb Haemost, Atherosclerosis, Int J Cardiol and other international authoritative journal. More than 70 papers has been indexed by SCI, the cumulative impact factor of which was as high as 200.

His team has won the second and third prize of medical science and technology in Chinese Medical Association, the second prize of the science and technology progress awarded by Ministry of education, the first and second prize of the introduction of new technology and the second prize of medical science and technology in Jiangsu Province.

Dr. Yang is specialized in biological therapy, especially gene therapy for ischemic myocardiopathy, and he is also applied to the tele- and moblie- medicine of coronary artery disease.

Time Visits: Monday morning


Department Characteristic, Advantage Technology:

  • Biological therapy, especially gene therapy for ischemic myocardiopathy;

  • Tele- and mobile- medicine for coronary artery disease;

  • Molecular epidemiology for coronary artery disease;

  • Individualized antiplatelet for post-PCI and post-CABG;

  • Magnetic navigation guided PCI for coronary artery disease;

  • Reverse PCI for CTO lesion;

  • Small incision CABG for beating heart;

  • Rapid alert for coronary artery disease.

  • medical equipment

  • Intra-aortic balloon pump (IABP)

  • Intravascular ultrasound scan (IVUS)

  • Optical coherence tomography (OCT)

  • Fractional flow reserve (FFR)

  • Coronary rotational atherectomy systems

  • Magnetic navigation system (MNS)

  • Catheter-based intramyocardial delivery (NavX)


Medical Equipment

  •  Coronary artery disease 

  •  Ischemic myocardiopathy 

  •  Chronic total coronary occlusion (CTO) 

  •  Coronary bifurcation lesions

  •  Coronary left main lesions

  •  Severe coronary calcified lesions

  •  Coronary borderline lesions

  •  Coronary microcirculatory disturbance

  •  Hypertrophic cardiomyopathy 


Since 2011, our center began to send out the excellent staff abroad every year for participating the international meeting, such as AHA, ESC, TCT and so on. Besides, our center held cooperative meeting every year as follows:

  •  China Innovation in Cardiology (CIC)——innovation forum of coronary artery disease.

  •  CTO CLUB of Jiangsu Province together with Japanese CTO specialist.

  •  Communication with Prof. Chuanfu Li, Quillen College of Medicine, East Tennessee State University, Johnson City, TN, USA.

 


Copyrights © 1936-2017 All Rights Reserved Jiangsu Province Hospital Affiliated to Nanjing Madical University of Medicine